Key result
Genomics-inspired biomarkers and diagnostics have not yet replaced traditional single-analyte markers like cTnI and BNP in cardiovascular medicine due to challenges in clinical translation.
Answers are grounded in this paper and cite their sources.
Despite advances in genomics, cardiovascular medicine continues to rely on traditional biomarkers like BNP and troponin, highlighting challenges in translating omics technologies into clinical practice.
Since the inception of the Human Genome Project in the late 1980s there has been unprecedented growth in the technologies to assay nucleic acids, proteins, and metabolic analytes at scale. One might have expected a concomitant increase in the development and delivery for use in the clinic of genome-inspired biomarkers and diagnostics; but, as this special cardiovascular issue of Clinical Chemistry demonstrates, the field continues to be denominated by old friends such as cardiac troponin I (cTnI),2 B-type natriuretic (BNP), and other single-analyte markers, albeit with greater analytical sensitivity and, as a result, broader potential applicability. It is disappointing not to see more from genomics given that the field of cardiovascular medicine aspires to be more precise in risk assessment, early and accurate diagnosis, and in the treatment and monitoring of disease. Most cardiovascular biomarker and diagnostics have been introduced using disease hypotheses based on known biology. BNP and cTnI are great examples that have revolutionized our ability to distinguish cardiac from pulmonary etiologies of dyspnea, to risk stratify patients with heart failure, and guide therapies in acute coronary syndromes. Unbiased and hypothesis-generating approaches using genomics, transcriptomics, proteomics, and metabolomics have great potential to deliver novel biomarkers and assays for the practice of cardiovascular precision medicine, but have challenges in their path to becoming accepted and useful clinically.
No takes yet. Share an insight, caveat, or question.
Geoffrey S. Ginsburg (2016) conducted an editorial in Cardiovascular disease. Genomics-inspired biomarkers vs. Traditional single-analyte markers (cTnI, BNP) was evaluated. Genomics-inspired biomarkers and diagnostics have not yet replaced traditional single-analyte markers like cTnI and BNP in cardiovascular medicine due to challenges in clinical translation.
Synapse has enriched 10 related papers. Consider them for comparative context: